Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity stays at 'speculative buy' on Aurrigo International

(Sharecast News) - Analysts at Canaccord Genuity reiterated their 135.0p target price on airside solutions developer Aurrigo International on Wednesday following the group's "positive" year-end trading update a day earlier. Aurrigo's trading update indicated FY24 revenues of £8.9m, in line with Canaccord Genuity's estimates, cash of £3.0m, also in line, and an underlying loss of £1.9m, ahead of expectations of a £2.7m loss.

Canaccord said the better-than-expected earnings were down to the capitalisation of certain development expenses in Aurrigo's autonomous division, in particular relating to its auto-cargo project with UPS.

The Canadian bank made "no material changes" to its 2025 forecasts but updated 2024 numbers to account for its better-than-expected earnings performance.

Before then, we expect there to be further positive progress, notably both on the ADT implementation with Singapore Changi and on the auto-cargo project," said Canaccord, which reiterated its 'speculative buy' rating on the stock. "The company also highlighted that following the completion of the £5.25mn funding round in January it remains well capitalised to support the next phase of growth."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.